Attending World ADC Europe 2025 in London, UK between March 3-6? Make sure to connect with Abzena’s drug development experts while you are there.

As a leading bioconjugates and ADC CDMO+CRO we welcome the opportunity to schedule some time to connect on your project-specific needs, and to provide you with an update on our expanded global capabilities. There is no therapeutic modality generating as much excitement as antibody-drug conjugates (ADCs). World ADC Europe is the annual touchpoint for the scientific community held in London, UK. Do not miss your chance to meet our ADC experts at the premier forum to leverage our unparalleled knowledge across cutting-edge R&D, end-to-end development strategy, and global market insights.

Abzena attendees include;

• Dr Petra Dieterich – Senior Vice President & Scientific Leader
• Dr Johanna Midelet – Head of Bioconjugation & Chemistry
• Dr Gavin Birch – Chemistry Manager (ADCs & Bioconjugates)
• Gavin Murdoch – Senior Vice President, Commercial Strategy
• Roger Bowie – Vice President, Business Development
• Gildas Lavenant – Vice President, Business Development
• Greg Downs – Vice President, Business Development

 
Hear from two of Abzena’s bioconjugation experts at WADC London as they present on ADC design strategies for AOCs, linker payloads and ADC discovery.

Presentation: Harnessing ADC Design Strategies for Next-Generation AOCs

Discovery Track: Tuesday March 4, 11:30, Dr Gavin Birch – Chemistry Manager

Hear from Dr Gavin Birch, Chemistry Manager on;

• Expanding architecture of linker payload and conjugation modality for AOCs
• Solving the challenges of next generation conjugates using Thiobridge® technology
• Supporting characterization and manufacture of bioconjugates through Abzena’s integrated offering

Presentation: Strategies in Early-Stage ADC Discovery for Design of Successful Lead Candidates for Clinical Development

Process & Analytical Development Track: Tuesday March 4, 12:30, Dr Johanna Midelet – Head of Bioconjugation & Chemistry

Hear from Dr Johanna Midelet, Head of Bioconjugation & Chemistry on;

• Designing ADCs for successful clinical development
• Using Thiobridge® conjugation and linker technology to build ADCs with payload diversity
• Modelling complex cell environments in vitro to ensure optimal ADC lead selection – a case study

We look forward to connecting with you at World ADC London. Please use the form below to schedule a meeting with our team.

About Abzena

Abzena is the leading end-to-end bioconjugate and complex biologics and bioconjugates CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. We enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. We have R&D, end-to-end development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.

Why Abzena?